Sign In
Buy CUE
$26.84
-3.56 (-11.71%)
At Close: Jul 31, 2026
Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q1 2021 Results - Earnings Call Transcript
11:19pm, Monday, 17'th May 2021
Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q1 2021 Results - Earnings Call Transcript
Strength Seen in Cue Biopharma, Inc. (CUE): Can Its 27.7% Jump Turn into More Strength?
09:46am, Tuesday, 11'th May 2021
Cue Biopharma, Inc. (CUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength d
Cue Biopharma's Stock Shoots Up After CUE-101 Shows Promise In Early-Stage Head & Neck Cancer Study
01:14pm, Monday, 10'th May 2021
Cue Biopharma Inc (NASDAQ: CUE) has announced interim clinical data from its ongoing Phase 1a/1b monotherapy study of CUE-101 as second-line treatment for patients with human papilloma virus-posit
Market Update: The 10 Most Volatile Stocks Today
12:38pm, Monday, 10'th May 2021
Joins us as we take a look at the most volatile stocks for Monday as many shares see their prices fluctuate during the day. The post Market Update: The 10 Most Volatile Stocks Today appeared first on
Cue Biopharma to Host Business Update Call and Webcast
10:00am, Monday, 10'th May 2021
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selective
CUE Stock: Over 10% Increase Pre-Market Explanation
08:54am, Monday, 10'th May 2021
The stock price of Cue Biopharma Inc (NASDAQ: CUE) increased by over 10% pre-market. This is why it happened.
Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q4 2020 Results - Earnings Call Transcript
11:04pm, Tuesday, 16'th Mar 2021
Cue Biopharma, Inc. (CUE) CEO Daniel Passeri on Q4 2020 Results - Earnings Call Transcript
Cue Biopharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
04:01pm, Tuesday, 16'th Mar 2021
CAMBRIDGE, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selecti
Cue Biopharma to Host Business Update Call and Webcast
08:00am, Tuesday, 09'th Mar 2021
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selecti
Cue Biopharma to Present at the Cowen 41st Annual Health Care Conference
08:00am, Monday, 01'st Mar 2021
CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selecti
Cue Biopharma Announces Appointment of Matteo Levisetti, M.D. as Senior Vice President of Clinical Development
08:00am, Wednesday, 17'th Feb 2021
Appointment to strengthen clinical development capabilities with a strategic and visionary immunotherapy leader as Cue Biopharma advances its pipeline of drug development programs
NexImmune Proposes Terms For $75 Million IPO
01:18pm, Monday, 08'th Feb 2021
NexImmune Proposes Terms For $75 Million IPO
7 Stocks With Insider Buying This Week Worth A Look
03:34pm, Friday, 29'th Jan 2021
Insider buying is often a profitable signal for bulls. Insiders only buy for one reason: they believe their company's stock is going higher.
Cue Biopharma: CUE-101's Phase 1 Promising Progress, 1 New IND Expected, Funding Until Q2 2022
06:37pm, Thursday, 07'th Jan 2021
Cue Biopharma is a clinical-stage biopharmaceutical company developing novel injectables that modulate targeted T-cells. Cue Biopharma has expanded its pipeline to include 7 therapeutics with 1 underg
Cue Biopharma to Present at the Piper Sandler 32nd Annual Healthcare Conference
08:00am, Monday, 23'rd Nov 2020
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectiv
